With 25 years of expertise in cell therapy, immunology and virology across fundamental, translational and clinical stages, Etablissement Français du Sang (EFS) combines strong capabilities in translational research, GMP-grade bioproduction and access to high-quality biological samples.

EFS operates four ATMP bioproduction platforms across France as a CDMO, supporting clinical manufacturing for a broad range of cell types including MSC, CAR-T, iPSC, hESC and HSC. EFS also performs the GMP manufacturing of cell banks (Master & Working) for its partners.

In addition, EFS has strenghten its offer, through its PIBT (Pôle d’Innovation en Biothérapies), a dedicated development platform, focused on the maturation of advanced therapy projects. This includes the evaluation and integration of innovative bioproduction technologies, process and analytical development, and scalability, with early consideration of manufacturing and GMP constraints.

Together, these capabilities provide a continuum from early-stage development to clinical production, enabling a smoother and more reliable transition toward industrialisation.